In late November CTA was pleased to host our second Developmental Therapeutics Update Dinner meeting for 2023, presented with the generous support of the Series sponsors, namely Amgen, AstraZeneca, BeiGene, GSK, IQVIA, Pfizer, Roche and Sanofi.

In 2023 over 170 site staff registrations were received across both dinners, where key highlights from major international meetings were presented by both clinicians and research staff.  Attendee feedback from the 2022 meetings led to the incorporation of networking time on the agendas, and a focus on the preferred function room style venues.

Associate Professor Ben Tran, Chair of the CTA Phase 1 Group, curated both agendas across 2023, ensuring a mix of solid tumour and blood cancer focused presentations, as well as incorporation of insightful key learnings from research nurses.

Given the strong interstate attendance, CTA also took the opportunity to host a national Phase 1 strategy meeting immediately prior to the November dinner, outcomes of which will be reported separately.

CTA would like to thank all who attended both dinners in 2023, particularly those who prepared and presented informative talks.

We look forward to welcoming all again in 2024.